日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Reply to Saleh, C.; Budincevic, H. Interleukin-6, Tocilizumab and Atherosclerosis. Comment on "Gerasimova et al. Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis. Int. J. Mol. Sci. 2024, 25, 12425"

回复 Saleh, C.; Budincevic, H. 白细胞介素-6、托珠单抗和动脉粥样硬化。评论“Gerasimova 等人,《白细胞介素-6:类风湿性关节炎患者长期细胞因子抑制的心血管方面》,《国际分子科学杂志》,2024, 25, 12425”。

Gerasimova, Elena; Popkova, Tatiana V; Kirillova, Irina G; Gerasimova, Daria; Nasonov, Evgenii L; Lila, Aleksandr M

The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial

在一项随机对照试验中,合并症对IL-6抑制剂olokizumab与adalimumab疗效的影响

Feist, Eugen; Luggen, Michael E; Nasonov, Evgeny L; Yakushin, Sergey S; Bukhanova, Daria V; Egorova, Alina N; Grishin, Sergey A; Samsonov, Mikhail Y; Smolen, Josef S

Autoantigenic peptide landscape of rheumatoid arthritis-associated HLA class II

类风湿性关节炎相关HLA II类分子的自身抗原肽图谱

Ishina, Irina A; Zhiyanov, Anton P; Kurbatskaia, Inna N; Mamedov, Azad E; Nersisyan, Stepan A; Ziganshin, Rustam H; Eliseev, Igor E; Petrusenko, Yunna S; Nikonova, Anastasia V; Zhbanova, Elizaveta S; Salnikova, Maria A; Ovchinnikova, Leyla A; Mamedov, Ilgar Z; Davydov, Alexey N; Nurbaeva, Kamila S; Lisitsyna, Tatiana A; Reshetnyak, Tatiana M; Lila, Alexander M; Nasonov, Evgeniy L; Lomakin, Yakov A; Belogurov, Alexey A Jr; Zhang, Hongkai; Tonevitskiy, Alexander G; Rubtsov, Yury P; Gabibov, Alexander G; Zakharova, Maria Y

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

奥洛珠单抗联合甲氨蝶呤:106周治疗的安全性和有效性

Feist, Eugen; Fleischmann, Roy M; Fatenejad, Saeed; Bukhanova, Daria; Grishin, Sergey; Kuzkina, Sofia; Luggen, Michael; Nasonov, Evgeniy; Samsonov, Mikhail; Smolen, Josef S

Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis.

白细胞介素-6:类风湿性关节炎患者长期细胞因子抑制的心血管方面

Gerasimova Elena V, Popkova Tatiana V, Kirillova Irina G, Gerasimova Daria A, Nasonov Evgenii L, Lila Aleksandr M

Are the Goals of Therapy Achievable in Patients with Rheumatoid Arthritis Receiving Upadacitinib in Real Clinical Practice?

在真实的临床实践中,接受乌帕替尼治疗的类风湿性关节炎患者的治疗目标是否能够实现?

Amirdzhanova, V N; Karateev, A E; Pogozheva, E Yu; Filatova, E S; Samigullina, R R; Mazurov, V I; Anoshenkova, O N; Lapkina, N A; Baranov, A A; Grineva, T Yu; Lila, A M; Nasonov, E L

Contributing Factors of Diabetes Mellitus among Patients with Gout (Results of the Long-Term Prospective Study)

痛风患者合并糖尿病的危险因素(长期前瞻性研究结果)

Zheliabina, O V; Eliseev, M S; Glukhova, S I; Nasonov, E L

Anti-topoisomerase 1 Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis

系统性硬化症B细胞清除疗法后抗拓扑异构酶1抗体水平的变化

Ananyeva, L P; Garzanova, L A; Koneva, O A; Starovoytova, M N; Desinova, O V; Ovsyannikova, O B; Shayakhmetova, R U; Cherkasova, M V; Aleksankin, A P; Nasonov, E L

Global Antiphospholipid Syndrome Score (GAPSS) in Patients with Systemic Lupus Erythematosus

系统性红斑狼疮患者的全球抗磷脂综合征评分(GAPSS)

Cheldieva, F A; Reshetnyak, T M; Shumilova, A A; Nurbaeva, K S; Cherkasova, M V; Lila, A M; Nasonov, E L

Antibodies to Domain I β(2)-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus

抗磷脂综合征和系统性红斑狼疮患者体内针对结构域 I β(2)-糖蛋白 1 的抗体

Reshetnyak, T M; Cheldieva, F A; Cherkasova, M V; Glukhova, S I; Lila, A M; Nasonov, E L